EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)

Ida Schregel iD, Maria Papp iD, Nora Sipeki iD, Patricia J Kovats iD, Richard Taubert iD, Bastian Engel iD, Alejandro Campos-Murguia iD, George N Dalekos iD, Nikolaos Gatselis iD, Kalliopi Zachou iD, Piotr Milkiewicz iD, Maciej K Janik iD und 8 weitere

Liver International · 2024

DOI: 10.1111/liv.16035 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, 2024. Verfasst von Ida Schregel und 19 weiteren Autor:innen. Beteiligte Einrichtung: I. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Hepatitis, Autoimmune, Registries, Alanine Transaminase. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The European Reference Network on Hepatological Diseases (ERN RARE‐LIVER) launched the prospective, multicentre, quality‐controlled R‐LIVER registry on rare liver diseases. The aim of this study was to assess the presentation and outcome of autoimmune hepatitis (AIH) after 1 year of treatment.

Methods

Data were prospectively collected at the time of diagnosis and after 6 and 12 months follow‐up. Complete biochemical response (CBR) was defined as normalization of alanine aminotransferase (ALT) and immunoglobulin G (IgG) serum levels.

Results

A total of 231 patients from six European centres were included in the analysis. After 6 months of treatment 50% (106/212), and after 12 months 63% (131/210) of patients reached CBR with only 27% (56/211) achieving a steroid‐free CBR within the first year. Overall, 16 different treatment regimens were administered. Change of treatment, mostly due to intolerance, occurred in 30.4% within the first 6 months. In multivariate analysis, younger age at diagnosis (odds ratio [OR] = 1.03 [95% confidence interval (CI) 1.01–1.05]; p = .007), severe fibrosis (OR .38 [95% .16–.89], p = .026) and change of treatment within the first 6 months (OR .40 [95% CI .2–.86]; p = .018) were associated with a lesser chance of ALT normalization at 12 months follow‐up.

Conclusion

The landscape of AIH treatment in Europe is highly heterogeneous, even between expert centres. The results from this first European multicentre prospective registry reveal several unmet needs, highlighted by the overall low rates of CBR and the frequent failure to withdraw corticosteroids.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis, AutoimmuneRegistriesAlanine TransaminaseHumansFemaleMaleMiddle AgedProspective StudiesEuropeAdultAgedImmunosuppressive AgentsImmunoglobulin GMultivariate AnalysisTreatment OutcomeYoung AdultLogistic ModelsLiver Cirrhosis

Stichwörter der Autor:innen

autoimmune hepatitiscomplete biochemical responseimmunosuppressionremissiontreatment regime

Substanzen

Alanine TransaminaseImmunosuppressive AgentsImmunoglobulin G

Autor:innen und Institutionen

  • I. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • European Reference Network (ERN) RARE-LIVER, Hamburg, Germany.
  • Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Hungary, Germany.
  • Faculty of Medicine, Kálmán Laki Doctoral School, University of Debrecen, Hungary, Germany.
  • Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
  • Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.

ORCID-Profile: Ida Schregel, Maria Papp, Nora Sipeki, Patricia J Kovats, Richard Taubert, Bastian Engel, Alejandro Campos-Murguia, George N Dalekos, Nikolaos Gatselis, Kalliopi Zachou, Piotr Milkiewicz, Maciej K Janik, Joanna Raszeja-Wyszomirska, Henriette Ytting, Christian Casar, Marcial Sebode, Ansgar W Lohse, Christoph Schramm

Zitieren

APA

Schregel, I., Papp, M., Sipeki, N., Kovats, P. J., Taubert, R., Engel, B., Campos-Murguia, A., Dalekos, G. N., Gatselis, N., Zachou, K., Milkiewicz, P., Janik, M. K., Raszeja-Wyszomirska, J., Ytting, H., Braun, F., Casar, C., Sebode, M., Lohse, A. W., Schramm, C., & European Reference Network (ERN) RARE‐LIVER (2024). Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER). Liver International. https://doi.org/10.1111/liv.16035

Vancouver

Schregel I, Papp M, Sipeki N, Kovats PJ, Taubert R, Engel B, et al. Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER). Liver International. 2024. doi:10.1111/liv.16035

BibTeX
@article{Schregel2024,
  author = {Schregel, Ida and Papp, Maria and Sipeki, Nora and Kovats, Patricia J and Taubert, Richard and Engel, Bastian and Campos-Murguia, Alejandro and Dalekos, George N and Gatselis, Nikolaos and Zachou, Kalliopi and Milkiewicz, Piotr and Janik, Maciej K and Raszeja-Wyszomirska, Joanna and Ytting, Henriette and Braun, Felix and Casar, Christian and Sebode, Marcial and Lohse, Ansgar W and Schramm, Christoph and European Reference Network (ERN) RARE‐LIVER, European Reference Network (ERN) RARE‐LIVER},
  title = {Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)},
  journal = {Liver International},
  year = {2024},
  doi = {10.1111/liv.16035}
}
Kostenlos starten →